C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026)

C4 Therapeutics' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $25.6 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 45.26% year-over-year to $25.6 million; the TTM figure through Mar 2026 stood at $25.6 million (down 45.26% YoY), while the FY2025 annual figure was $28.3 million, up 51.42% from the prior year.
• Current Deferred Revenue was $25.6 million for Q1 2026 at C4 Therapeutics, down from $28.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $49.4 million in Q3 2024 to a low of $8.4 million in Q3 2023.
• Historically, Current Deferred Revenue has averaged $29.1 million across 5 years, with a median of $30.8 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue tumbled 75.86% in 2023, then jumped 486.62% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $33.5 million in 2022, then plunged by 53.84% to $15.5 million in 2023, then gained by 20.95% to $18.7 million in 2024, then soared by 51.42% to $28.3 million in 2025, then fell by 9.78% to $25.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $25.6 million (Q1 2026), $28.3 million (Q4 2025), and $17.1 million (Q3 2025), per Business Quant data.